Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | PRKCG | P05129 | 1/20 | 0.31 |
| ▸ | PRKCB | P05771 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PRKCH | P24723 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.31 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12053823 | 1.00 | BIRC2 (0.34) | BIRC2CCR2KDM4ECYP3A4CYP2D6 | |
| SCHEMBL12053826 | 1.00 | BIRC2 (0.34) | BIRC2CCR2KDM4ECYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL31094861 | 0.98 | CCR2 (0.33) | BIRC2CCR2KDM4ECYP3A4CYP2D6 | |
| SCHEMBL12368090 | 0.86 | BIRC2 (0.33) | BIRC2 | |
| SCHEMBL18369742 | 0.79 | — | — | |
| SCHEMBL26604181 | 0.79 | ATM (0.31) | CCR2 | |
| SCHEMBL28274260 | 0.79 | ATM (0.31) | CCR2 | |
| SCHEMBL26746500 | 0.79 | BIRC2 (0.34) | BIRC2KDM4ECYP3A4CYP2D6NFKB1 | |
| SCHEMBL24429551 | 0.77 | CCR2 (0.30) | CCR2 | |
| SCHEMBL20618282 | 0.77 | CCR2 (0.33) | CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112513036-B | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | 福马治疗有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117881678-A | Compound with SHP2 protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117794933-A | Phenol derivatives for modulating BRM | 基因泰克公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-117658987-A | Compounds as PLK1 inhibitors, and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117645614-A | Substituted heterocyclo-cyclic compounds, preparation and pharmaceutical use thereof | 劲方医药科技(上海)有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| CN-116854680-A | Isoxazole-heterocycle derivatives, pharmaceutical composition and application | 上海赛默罗生物科技有限公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-116670136-A | Tetracyclic compound and medical application thereof | 正大天晴药业集团股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| CN-116535412-A | Polycyclic compounds as SOS1 inhibitors | 昆药集团股份有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | KURA ONCOLOGY, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20110213152-A1 | METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110077237-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-31 | — | — | US | disclosed |
| US-7902365-B2 | Using a 2-sulfone, 3-carboxylate, 4-oxoquinoline as chemical intermediate ; cyclization | ACHILLION PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7781426-B2 | cholesterol ester transfer protein (CETP) inhibitors such as (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[2-(3,3-dimethylpiperidin-1-yl)-5-(trifluoromethyl)benzyl]-4-methyl-1,3-oxazolidin-2-one, useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis | MERCK SHARP & DOHME CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781426-B2 | cholesterol ester transfer protein (CETP) inhibitors such as (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[2-(3,3-dimethylpiperidin-1-yl)-5-(trifluoromethyl)benzyl]-4-methyl-1,3-oxazolidin-2-one, useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis | MERCK SHARP & DOHME CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-7524839-B2 | Compounds, their use and preparation | BIOVITRUM AM (PUBL.) | 2009-04-28 | — | — | US | disclosed |
| US-20090075979-A1 | CETP Inhibitors | MERCK SHARP & DOHME LLC | 2009-03-19 | — | — | US | disclosed |
| US-20080071086-A1 | METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES | ACHILLION PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| US-20080044355-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | VERTEX PHARMACEUTICALS INCORPORATED | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075979-A1 | CETP Inhibitors | CETP, APOB, MTTP | BIRC2 3759/4885CCR2 1314/4885KDM4E 1388/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | BIRC2 1288/4885CCR2 2597/4885KDM4E 990/4885 |
| US-20230365563-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | KRAS, NRAS, BRAF | BIRC2 2471/4885CCR2 2885/4885KDM4E 4039/4885 |
| US-20080044355-A1 | including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease | CFTR, ABCB4, ABCF2 | BIRC2 4032/4885CCR2 3981/4885KDM4E 3212/4885 |
| US-11673898-B2 | Substituted inhibitors of menin-MLL and methods of use | MLLT1, MEN1, MLLT3 | BIRC2 543/4885CCR2 3773/4885KDM4E 151/4885 |
| US-20110213152-A1 | METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES | QDPR, CYP4B1, DRD4 | BIRC2 1941/4885CCR2 930/4885KDM4E 573/4885 |
| US-20110077237-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | BIRC2 1288/4885CCR2 2597/4885KDM4E 990/4885 |
| US-20080071086-A1 | METHOD FOR SYNTHESIS OF 8-ALKOXY-9H-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES | QDPR, CYP4B1, DRD4 | BIRC2 1941/4885CCR2 930/4885KDM4E 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.